Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
904.4 DKK | +2.40% | +6.28% | +29.49% |
May. 10 | Roughly 1 in 8 US adults have taken GLP-1 drugs like Wegovy, poll shows | RE |
May. 10 | India's Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+29.49% | 568B | |
+30.38% | 684B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.00% | 240B | |
+9.34% | 208B | |
-7.28% | 200B | |
+7.68% | 166B | |
-2.71% | 159B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Lars Fruergaard Jorgensen, CEO of Novo Nordisk: dose limitation to continue until 2024